Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

Författare

  • Amanda B. Spurdle
  • Louise Marquart
  • Lesley McGuffog
  • Sue Healey
  • Olga Sinilnikova
  • Fei Wan
  • Xiaoqing Chen
  • Jonathan Beesley
  • Christian F. Singer
  • Anne-Catharine Dressler
  • Daphne Gschwantler-Kaulich
  • Joanne L. Blum
  • Nadine Tung
  • Jeff Weitzel
  • Henry Lynch
  • Judy Garber
  • Douglas F. Easton
  • Susan Peock
  • Margaret Cook
  • Clare T. Oliver
  • Debra Frost
  • Don Conroy
  • D. Gareth Evans
  • Fiona Lalloo
  • Ros Eeles
  • Louise Izatt
  • Rosemarie Davidson
  • Carol Chu
  • Diana Eccles
  • Christina G. Selkirk
  • Mary Daly
  • Claudine Isaacs
  • Dominique Stoppa-Lyonnet
  • Olga M. Sinilnikova
  • Bruno Buecher
  • Muriel Belotti
  • Sylvie Mazoyer
  • Laure Barjhoux
  • Carole Verny-Pierre
  • Christine Lasset
  • Helene Dreyfus
  • Pascal Pujol
  • Marie-Agnes Collonge-Rame
  • Matti A. Rookus
  • Senno Verhoef
  • Mieke Kriege
  • Nicoline Hoogerbrugge
  • Margreet G. E. M. Ausems
  • Theo A. van Os
  • Juul Wijnen
  • Peter Devilee
  • Hanne E. J. Meijers-Heijboer
  • Marinus J. Blok
  • Tuomas Heikkinen
  • Heli Nevanlinna
  • Anna Jakubowska
  • Jan Lubinski
  • Tomasz Huzarski
  • Tomasz Byrski
  • Francine Durocher
  • Fergus J. Couch
  • Noralane M. Lindor
  • Xianshu Wang
  • Mads Thomassen
  • Susan Domchek
  • Kate Nathanson
  • M. A. Caligo
  • Helena Jernström
  • Annelie Liljegren
  • Hans Ehrencrona
  • Per Karlsson
  • Patricia A. Ganz
  • Olufunmilayo I. Olopade
  • Gail Tomlinson
  • Susan Neuhausen
  • Antonis C. Antoniou
  • Georgia Chenevix-Trench
  • Timothy R. Rebbeck

Summary, in English

Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies. Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated. Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk. Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers. Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5); 1032-38. (C) 2011 AACR.

Avdelning/ar

  • Bröstcancer-genetik
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publiceringsår

2011

Språk

Engelska

Sidor

1032-1038

Publikation/Tidskrift/Serie

Cancer Epidemiology Biomarkers & Prevention

Volym

20

Issue

5

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research

Ämne

  • Cancer and Oncology

Nyckelord

  • Single Nucleotide
  • Polymorphism
  • Humans
  • Heterozygote
  • Germ-Line Mutation
  • Genotype
  • Genetic Predisposition to Disease
  • Female
  • Cohort Studies
  • Breast Neoplasms
  • BRCA1 Protein
  • BRCA2 Protein
  • Prognosis
  • Risk Factors
  • Tumor Markers
  • Biological
  • Tumor Suppressor Proteins
  • Ubiquitin-Protein Ligases

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1538-7755